Is Dr Agarwal's Eye overvalued or undervalued?

As of 31 October 2025, Dr Agarwal's Eye has moved from an expensive to a fair valuation grade. The company is currently fairly valued, with a PE ratio of 40.18, an EV to EBITDA ratio of 16.40, and a Price to Book Value of 0.80. In comparison to its peers, Max Healthcare is very expensive with a PE ratio of 92.62, while Apollo Hospitals is attractive with a PE ratio of 70.17, highlighting Dr Agarwal's relative positioning in the market.
Despite a recent decline in stock performance with a year-to-date return of -14.55%, the company's long-term performance remains strong, with a 3-year return of 304.96%. The valuation metrics suggest that Dr Agarwal's Eye is positioned reasonably within its industry, providing a fair investment opportunity at its current price of 5,235.70.